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Abstract
The increasing emergence of multidrug-resistant pathogens is one of the biggest threats to human health and food security. The
discovery of new antibacterials, and in particular the finding of new scaffolds, is an imperative goal to stay ahead of the evolution
of antibiotic resistance. Herein we report the synthesis of a 3-decyltetramic acid analogue of the ureido dipeptide natural antibiotic
leopolic acid A. The key step in the synthetic strategy is an intramolecular Lacey–Dieckmann cyclization reaction of a linear pre-
cursor to obtain the desired 3-alkyl-substituted tetramic acid core. The synthesized analogue is more effective than the parent
leopolic acid A against Gram-positive (Staphylococcus pseudintermedius) and Gram-negative (E. coli) bacteria (MIC 8 µg/mL and
64 µg/mL, respectively). Interestingly, the compound shows a significant activity against Staphylococcus pseudintermedius strains
expressing a multidrug-resistant phenotype (average MIC 32 µg/mL on 30 strains tested). These results suggest that this molecule
can be considered a promising starting point for the development of a novel class of antibacterial agents active also against resis-
tant strains.
Introduction
The treatment of bacterial infections by antibiotics is widely
regarded as one of the major achievements of the 20th century.
However, the continued emergence of multidrug-resistant
bacteria, mainly due to the abuse of antimicrobial molecules
(e.g., for treatment of bacterial skin diseases [1]), emphasises
the urgent need for novel antibiotic families. In this regard,
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Figure 1: Structures of leopolic acid A and compound 1.
natural products are privileged compounds, as they possess bio-
logically validated structures, which could become suitable
leads in drug discovery [2].
Recently, our research group reported the first total synthesis of
leopolic acid A (Figure 1), a fungal metabolite from a terres-
trial-derived Streptomyces sp. isolated from the rhizosphere of
the plant Juniperus excelsa [3,4]. Leopolic acid A is endowed
with antibacterial activity against Staphylococcus aureus and
Staphylococcus pseudintermedius with a MIC of 16 μg/mL, and
against Escherichia coli with a MIC of 128 µg/mL [3,4]. In
terms of structural features, this compound contains a 4-decyl-
2,3-pyrrolidinedione ring linked to the ureido dipeptide L-Phe-
L-Val. The 2,3-pyrrolidinedione ring is a quite unusual
skeleton. A limited number of compounds containing this
system have been synthesized so far [5-7] and, to the best of our
knowledge, natural compounds with a 2,3-pyrrolidinedione
nucleus are quite rare [8-11]. The lack of similar compounds
may be due to the instability of the 2,3 pyrrolidinedione moiety
[12]. Indeed, while developing the total synthesis of leopolic
acid A, we encountered several difficulties in the construction
of the ring, most of the intermediates being unstable [4].
In light of these results, we intended to investigate the role of
the 2,3 pyrrolidinedione ring by replacing it with a more stable
isomeric 2,4-pyrrolidinedione moiety. Actually, 2,4 pyrrolidine-
diones (tetramic acids) have recently attracted considerable
attention for their antibacterial, antiviral, antifungal and anti-
cancer activities [13]. More than one hundred of them have
been isolated from a variety of natural sources and numerous
analogues have been synthesized and studied for their multiple
biological activities [13]. For this reason, we planned the syn-
thesis of a leopolic acid A analogue containing the tetramic acid
moiety in place of the 2,3-pyrrolidinone ring (compound 1),
while maintaining unchanged all the other structural features of
the natural compound. The advantage of this substitution should
be a higher stability of the heterocyclic ring, hopefully coupled
with an increased activity due to the presence of the tetramic
acid core.
In this paper we report the efforts made to develop a synthetic
strategy to compound 1, which may, in principle, have a value
in the preparation of various analogues for structure–activity
relationship (SAR) studies. The antibacterial activity of com-
pound 1 was tested on Staphylococcus pseudintermedius and
Escherichia coli strains chosen as representative of Gram-posi-
tive and Gram-negative bacteria. In particular, we demon-
strated the ability of compound 1 to inhibit Staphylococcus
pseudintermedius strains expressing a multidrug-resistant
phenotype.
Results and Discussion
The instability of most of the N-unsubstituted 2,3-pyrrolidine-
diones prepared for the construction of leopolic acid A [4]
forced us to develop a linear synthetic strategy consisting of
11 steps, not amenable for the preparation of analogues. Con-
versely, compound 1 appears well suited to a convergent syn-
thetic approach based around two fragments, the ureido dipep-
tide L-Phe-L-Val and the 3-decyltetramic acid core (Figure 1).
Initially, we focused on the synthesis of the 2,4-pyrrolidine-
dione core. A review of the existing literature on tetramic acids
syntheses revealed a considerable amount of papers regarding
the preparation of 3-acyltetramic acids [14-18], whereas the
synthesis of 3-alkyl-tetramic acids has been considerably less
investigated [19-22]. We envisaged that the most straightfor-
ward route to the 2,4-pyrrolidinedione system could be a
Lacey–Dieckmann cyclization starting from a N-acetoacetyl-α-
amino ester. Interestingly, the biosynthetic pathways of the
tetramic acid scaffold involves Lacey–Dieckmann cyclases [23]
or a spontaneous intramolecular Claisen condensation, which
occurs in the cytosol. To protect the α-amino ester nitrogen we
chose the p-methoxybenzyl (PMB) group, easily removable by
ceric ammonium nitrate (CAN). N-(4-Methoxybenzyl)glycine
ethyl ester (5) was obtained in 87% yield by reacting
4-methoxybenzylamine (3) with bromoacetic acid ethyl ester
(4) in THF (Scheme 1). The ester 5 was converted into com-
pounds 6a and 6b by condensation with monoethyl malonate
and monobenzyl malonate, in the presence of DCC and DMAP,
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Scheme 1: Synthesis of 3-decyltetramic intermediate 13. Reagent and conditions: a) TEA, THF, 0 °C to rt, 2.5 h, 87%; b) monoethyl malonate (for
6a), monobenzyl malonate (for 6b), DCC, DMAP, CH2Cl2, 0 °C to rt, 24 h (for 6a), 12 h (for 6b), 6a: 80%, 6b: 83%; c) TBAF, Et2O, THF, 1-iodode-
cane, rt, 24 h, 7a: 22%, 7b: 30%; d) CAN, CH3CN/H2O (3:1), 0 °C to rt, 1 h, 8a: 81%, 8b: 66%; e) dodecanoyl chloride, TEA, CHCl3, 0 °C to rt, 3 h,
90%; f) t-BuOK 1 M in THF, THF, reflux, 1.5 h, 65%; g) benzyl tosylate, KHMDS 0.5 M in toluene, crown ether 18-crown-6, THF, 0 °C to rt, 3 h, 35%;
h) TFA, 60 °C, 2h; i) CAN, CH3CN/H2O (3:1), 0 °C to rt, 1h; j) benzyl tosylate, KHMDS 0.5 M in toluene, crown ether 18-crown-6, THF, 0 °C to rt,
2.5 h, 30% over two steps.
in 80% and 83% yield, respectively. Starting from intermedi-
ates 6a and 6b, treatment with a tetrabutylammonium fluoride
solution in diethyl ether at room temperature induced the cycli-
sation and the formation of an enolate, which was subsequently
reacted with 1-iododecane and deprotected with ceric ammoni-
um nitrate to afford derivatives 8a and 8b, respectively. Unfor-
tunately, at this stage all attempts to decarboxylate compounds
8a and 8b failed [22]. To overcome the problem of decarboxyl-
ation, we planned to synthesize the alkyl-substituted tetramic
core in one single step by Lacey–Dieckmann cyclisation of
ethyl 2-(N-(4-methoxybenzyl)dodecanoylamino)acetate (9), al-
though this compound does not contain an active methylene
group. Thus, compound 5 was acylated with dodecanoyl chlo-
ride to obtain compound 9 in 90% yield. As expected, the cycli-
zation reaction was found to be quite troublesome. Several
attempts were made using different conditions (TBAF, Et2O, rt;
NaOEt, EtOH, reflux; NaH, THF, reflux; LDA, THF, −78 °C),
but they all were unsuccessful. Finally, we succeeded in prepar-
ing intermediate 10 by treatment of compound 9 with potas-
sium tert-butoxide (1 M in THF) in THF [24]. The optimisation
of reaction conditions, work-up and purification, allowed us to
obtain the desired compound in 65% yield.
Before removing the PMB group and installing the ureidodipep-
tide fragment, we needed to protect the oxygen at C-4 [15]. We
selected a benzyl protecting group, as it could be cleaved by
catalytic hydrogenation together with the benzyl ester of
L-phenylalanine in the ureidodipeptide fragment (see synthesis
of compound 20) by a one-pot reaction. To increase the reac-
tion rate toward O-alkylation, we used an aprotic polar solvent
like DMF, which weakly solvates the enolates. However, treat-
ment of compound 10 with benzyl bromide and K2CO3 in DMF
gave exclusively the C-3 alkylated derivative. Thus, we consid-
ered that a hard leaving group such as a sulfonate should play a
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Scheme 2: Synthesis of dipeptide L-Phe-L-Val intermediate 20. Reagents and conditions: a) PTSA·H2O, benzyl alcohol, toluene, reflux, 10 h, 70%;
b) HClO4, tert-butyl acetate, 0 °C, 1 h, then rt, 20 h, 75%; c) triphosgene, DIEA, DCM, rt, 3 h, 50%; d) trifluoroacetic acid, DCM, rt, 3 h, 95%;
e) pentafluorophenol, DCC, EtOAc, 0 °C, 1h, then rt, 3 h, 60%.
key role in favouring O-alkylation. Moreover, we selected a
base containing potassium as a metal cation, which provides a
greater electron density to the nucleophilic enolate, thus
favouring O-alkylation. Satisfyingly, O-selective alkylation of
compound 10 was achieved by deprotonation with KHMDS fol-
lowed by alkylation with benzyl tosylate in the presence of
18-crown-6 ether [15]. The synthesis of benzyl tosylate was
accomplished using benzyl alcohol and freshly recrystallized
p-toluenesulfonyl chloride in the presence of anhydrous tri-
methylamine and DMAP, in anhydrous dichloromethane [25].
At this stage, all attempts to obtain the key intermediate 13
removing the p-methoxybenzyl group [24,26-28] from 11
failed. Finally, compound 13 was successfully obtained by
modifying the sequence of reactions. Deprotection of com-
pound 10 with TFA [24], followed by selective alkylation with
benzyl tosylate as previously described, afforded the desired
O-alkyltetramic acid 13 in 30% yield.
The synthesis of the activated ureido fragment was achieved in
four steps from suitably protected L-valine and L-phenylala-
nine. The benzyl protection of L-phenylalanine (14) was carried
out with PTSA and benzyl alcohol in toluene and the ester 15
was isolated as its p-toluensulfonic acid salt by recrystallization
with Et2O in 70% yield (Scheme 2). L-valine (16) was pro-
tected as tert-butyl ester 17 by using perchloric acid in t-BuOAc
in 75% yield. The unsymmetrical urea 18 was synthesized using
triphosgene at room temperature in 50% yield. The tert-butyl
ester was easily cleaved by trifluoroacetic acid in DCM at room
temperature to furnish the corresponding acid 19 (yield 95%),
which was activated by pentafluorophenol, DCC in EtOAc to
give the pentafluorophenylester ureido-dipeptide 20 (60%,
Scheme 2).
With both key fragments 13 and 20 in hand, we finally accom-
plished the N-acylation reaction using n-BuLi in THF at −60 °C
[15] in 60% yield. Removal of both protecting groups by cata-
lytic hydrogenation, gave the desired compound 1 in 72% yield
(Scheme 3).
Compound 1 was subjected to a preliminary study to evaluate
the antimicrobial activity against 80 strains of Staphylococcus
pseudintermedius and 25 strains of Escherichia coli. Bacterial
isolates of S. pseudintermedius and E. coli, previously identi-
fied using selective and differential cultural media (e.g.,
Mannitol Salt Agar; MacConkey Agar, Oxoid, Italy), were iso-
lated on blood agar plates (Tryptic Soy Agar plus 5% defibri-
nated sheep blood, Microbiol, Italy) to obtain pure cultures [29].
The isolated colonies were used to assess the phenotypic profile
of antimicrobial resistance. For this purpose, the Kirby Bauer
disk diffusion method was used in accordance to Clinical Labo-
ratory Standards Institute guidelines [30]. All the strains were
treated with a panel of antimicrobial molecules belonging to
five pharmacological categories: amoxicillin + clavulanic acid,
cephalexin, cefovecin, clindamycin, doxycycline, enrofloxacin
and marbofloxacin. Only for S. pseudintermedius strains,
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Scheme 3: Synthesis of compound 1. Reagents and conditions: a) n-BuLi, THF, −60 °C, 220 min, 60%; b) H2, Pd/C 10%, AcOEt, rt, 100 min, 72%.
oxacillin was also tested to assess methicillin-resistance (see
Table S1, Supporting Information File 1, for details). After
incubation, 30 strains of S. pseudintermedius revealed
resistance phenoptype to three or more pharmacological cate-
gories and were considered multidrug resistant (MDR) [31].
MICs (minimum inhibitory concentrations) of compound 1
were evaluated on each bacterial strain (E. coli and S. pseudin-
termedius MDR or not) as reported by CLSI guidelines [30,32].
The average MIC values of 1 against 50 Staphylococcus pseud-
intermedius isolates were 8 μg/mL and versus Escherichia coli
64 μg/mL, lower than the MICs shown by the parent leopolic
acid A (Staphylococcus pseudintermedius average MIC
16 μg/mL; Escherichia coli average MIC 128 μg/mL) [4]. Inter-
estingly, compound 1 showed a significant activity also against
Staphylococcus pseudintermedius strains expressing a
multidrug-resistant phenotype (average MIC 32 µg/mL on
30 strains tested).
Conclusion
The development of novel strategies to fight bacterial infec-
tions is an imperative goal, mainly due to the increasing num-
ber of bacterial strains resistant to a wide spectrum of antibiot-
ics. Aim of this work was the development of a synthetic
strategy for obtaining new natural compound-derived scaffolds
endowed with increased antimicrobial activity. Attention was
focused on 2,4-pyrrolidinedione derivatives, so-called tetramic
acids. As part of our search for new tetramic acid containing
scaffolds, we have synthesized the 2,4-pyrrolidinone analogue
of the natural compound leopolic acid A, by a convergent syn-
thetic strategy. Compound 1 is more effective than the parent
leopolic acid A against Staphylococcus pseudintermedius and
E. coli strains (MIC 8 µg/mL and 64 µg/mL, respectively) and
Staphylococcus pseudintermedius strains expressing a
multidrug-resistant phenotype (average MIC 32 µg/mL on
30 strains tested). The results confirm that the replacement of
the 2,3-pyrrolidinedione core with the tetramic acid nucleus
leads to an increase of antimicrobial activity even on MDR
strains, thus suggesting that the new scaffold can be considered
as a promising candidate for further investigation. Efforts to
synthesize analogues of compound 1 to deepen the structure–ac-
tivity relationship (SAR) study of this novel class of antibacteri-
al agents are underway.
Supporting Information
Supporting Information File 1
General experimental methods, synthetic procedures and
analytical data for the reported compounds, antimicrobial
activity evaluation procedures.
[https://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-14-224-S1.pdf]
Supporting Information File 2
1H NMR and 13C NMR spectra of the new compounds;
COSY spectra of compounds 1, 10; HDMS spectra of
compound 1.
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